Literature DB >> 24703244

Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells.

Mirna Mourtada-Maarabouni1, Gwyn T Williams2.   

Abstract

BACKGROUND: Inhibition of the mammalian target of rapamycin (mTOR) pathway is a promising strategy for the treatment of mantle cell lymphoma (MCL). ncRNA growth arrest-specific 5 (GAS5), a 5' terminal oligopyrimidine (5'TOP) RNA regulated by the mTOR pathway, is necessary and sufficient for normal growth arrest in leukemic and untransformed human lymphocytes.
METHODS: We downregulated endogenous GAS5 in mantle cell lymphoma cell lines using RNA interference before treatment with several rapalogues. The effect of GAS5 downregulation was monitored by 3 independent analyses of cell viability, DNA synthesis, and colony-forming ability.
RESULTS: Downregulation of GAS5 substantially reduced the effects of each rapalogue on cell viability, DNA synthesis, and colony-forming ability.
CONCLUSION: Stimulation of expression of candidate tumor suppressor GAS5 is responsible for much of the cytotoxic and cytostatic effects of rapalogues in MCL, suggesting that improved targeting of this pathway may allow improvements in the therapy of this intractable lymphoma.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Non-Hodgkin lymphoma; Rapamycin; mTOR; ncRNA

Mesh:

Substances:

Year:  2014        PMID: 24703244     DOI: 10.1016/j.clml.2014.02.011

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  12 in total

1.  Long non-coding RNA growth arrest-specific transcript 5 in tumor biology.

Authors:  Xin Yu; Zheng Li
Journal:  Oncol Lett       Date:  2015-07-30       Impact factor: 2.967

Review 2.  Molecular and Cellular Mechanisms of Action of Tumour Suppressor GAS5 LncRNA.

Authors:  Mark R Pickard; Gwyn T Williams
Journal:  Genes (Basel)       Date:  2015-07-07       Impact factor: 4.096

3.  Long non-coding RNA GAS5 controls human embryonic stem cell self-renewal by maintaining NODAL signalling.

Authors:  Chen Xu; Yan Zhang; Qiaoling Wang; Zhenyu Xu; Junfeng Jiang; Yuping Gao; Minzhi Gao; Jiuhong Kang; Minjuan Wu; Jun Xiong; Kaihong Ji; Wen Yuan; Yue Wang; Houqi Liu
Journal:  Nat Commun       Date:  2016-11-04       Impact factor: 14.919

Review 4.  Long non-coding RNAs in B-cell malignancies: a comprehensive overview.

Authors:  Lucia Nobili; Domenica Ronchetti; Elisa Taiana; Antonino Neri
Journal:  Oncotarget       Date:  2017-04-20

Review 5.  Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.

Authors:  Duncan Ayers; Jo Vandesompele
Journal:  Genes (Basel)       Date:  2017-03-03       Impact factor: 4.096

Review 6.  Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy.

Authors:  Mette Dahl; Lasse Sommer Kristensen; Kirsten Grønbæk
Journal:  Int J Mol Sci       Date:  2018-08-21       Impact factor: 5.923

Review 7.  The Network of Non-coding RNAs in Cancer Drug Resistance.

Authors:  Fabio Corrà; Chiara Agnoletto; Linda Minotti; Federica Baldassari; Stefano Volinia
Journal:  Front Oncol       Date:  2018-08-29       Impact factor: 6.244

Review 8.  The Growth-Arrest-Specific (GAS)-5 Long Non-Coding RNA: A Fascinating lncRNA Widely Expressed in Cancers.

Authors:  Anton Scott Goustin; Pattaraporn Thepsuwan; Mary Ann Kosir; Leonard Lipovich
Journal:  Noncoding RNA       Date:  2019-09-17

9.  Drug Resistance-Related Competing Interactions of lncRNA and mRNA across 19 Cancer Types.

Authors:  Haizhou Liu; Shuyuan Wang; Shunheng Zhou; Qianqian Meng; Xueyan Ma; Xiaofeng Song; Lihong Wang; Wei Jiang
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-11

Review 10.  Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives.

Authors:  Mara Fernandes; Herlander Marques; Ana Luísa Teixeira; Rui Medeiros
Journal:  Biomedicines       Date:  2021-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.